Limits...
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY - Cancer Sci. (2014)

Bottom Line: Multivariate analyses demonstrated that good PS, invasive ductal carcinoma, non-triple negative phenotype and initial operable stage were significantly associated with a lower death risk.Our results also suggest that the prediction of docetaxel toxicity might be possible for C3435T polymorphism.This study results provides valuable information on individualized therapy according to genotypes.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

Show MeSH

Related in: MedlinePlus

ABCB1 C3435T polymorphism against plasma drug level. (a) Docetaxel concentration in plasma (P = 0.031). (b) Doxorubicin concentration in plasma (P = 0.104).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317776&req=5

fig02: ABCB1 C3435T polymorphism against plasma drug level. (a) Docetaxel concentration in plasma (P = 0.031). (b) Doxorubicin concentration in plasma (P = 0.104).

Mentions: The ABCB1 3435TT genotype showed a higher AUCdoc than the CC/CT genotype with statistical significance (P = 0.031) (Fig.2). However, the ABCB1 G2677T/A or C1236T genotypes showed no association with AUCdoc or AUCdox. Among the genotypes of CYP3A5, AA (*1/*1)/AG (*1/*3) genotypes had a higher AUC of docetaxel than the GG (*3/*3) genotype with statistical significance (P = 0.024). The ABCB1 3435TT genotype was correlated with neutropenia (P = 0.039), febrile neutropenia (P = 0.218), and diarrhea (P = 0.057). CYP3A5 polymorphism did not affect survival and toxicities.


ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY - Cancer Sci. (2014)

ABCB1 C3435T polymorphism against plasma drug level. (a) Docetaxel concentration in plasma (P = 0.031). (b) Doxorubicin concentration in plasma (P = 0.104).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317776&req=5

fig02: ABCB1 C3435T polymorphism against plasma drug level. (a) Docetaxel concentration in plasma (P = 0.031). (b) Doxorubicin concentration in plasma (P = 0.104).
Mentions: The ABCB1 3435TT genotype showed a higher AUCdoc than the CC/CT genotype with statistical significance (P = 0.031) (Fig.2). However, the ABCB1 G2677T/A or C1236T genotypes showed no association with AUCdoc or AUCdox. Among the genotypes of CYP3A5, AA (*1/*1)/AG (*1/*3) genotypes had a higher AUC of docetaxel than the GG (*3/*3) genotype with statistical significance (P = 0.024). The ABCB1 3435TT genotype was correlated with neutropenia (P = 0.039), febrile neutropenia (P = 0.218), and diarrhea (P = 0.057). CYP3A5 polymorphism did not affect survival and toxicities.

Bottom Line: Multivariate analyses demonstrated that good PS, invasive ductal carcinoma, non-triple negative phenotype and initial operable stage were significantly associated with a lower death risk.Our results also suggest that the prediction of docetaxel toxicity might be possible for C3435T polymorphism.This study results provides valuable information on individualized therapy according to genotypes.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

Show MeSH
Related in: MedlinePlus